LNT (Lacto-N-Tetraose) is a highly abundant neutral core HMO in human milk. Regulatory filings for LNT have been made in EU and US and preparation is on way for other major markets. GlyCare™ LNT will be commercially available from 2020.
HMO studies (clinical) suggest a relationship between human milk ologosaccharides and some immune outcomes in infants. Emerging science suggest that specific HMOs at the correct level of supplementation may help to reduce the risk of certain infections in infants consuming infant formula and in infants who are breastfed.
Emerging evidence from preclinical studies suggest that LNT may support immune health via inhibiting the adhesion of pathogens to cell walls1,2 and binding to toxins3.
Clinical and preclinical studies report that HMOs may help to stimulate the growth of beneficial bacteria, which are believed to be important for development of the microbiota and gut health. Evidence from preclinical studies suggests LNT may have a role in gut health via its positive impact on growth of bifidobacteria4,5,6.
1. Andersson, B., Dahmen, J., Tornbjorn, F., Leffler, H., Magnusson, G., Noori, G., & Svanborg Eden, C. (1983). IDENTIFICATION OF AN ACTIVE DISACCHARIDE UNIT OF A GLYCOCONJUGATE RECEPTOR FOR PNEUMOCOCCI ATTACHING TO HUMAN PHARYNGEAL EPITHELIAL CELLS. J. Epx. Med., 158(August).
2. Andersson, B., Porras, O., Hanson, L. Å., Svanborg Edén, C., & Leffler, H. (1985). Non-Antibody-Containing Fractions of Breast Milk Inhibit Epithelial Attachment of Streptococcus Pneumoniae and Haemophilus Influenzae. The Lancet, 325(8429), 643. https://doi.org/10.1016/S0140-6736(85)92184-1
3. El-Hawiet, A., Kitova, E. N., and Klassen, J. S. (2015). Recognition of human milk oligosaccharides by bacterial exotoxins. Glycobi- ology, 25(8):845–854.
4. Sela, D. A., Garrido, D., Lerno, L., Wu, S., Tan, K., Eom, H. J., Joachimiak, A., Lebrilla, C. B., and Mills, D. A. (2012). Bifidobac- terium longum subsp. infantis ATCC 15697 α-fucosidases are active on fucosy- lated human milk oligosaccharides. Applied and Environmental Microbiology, 78(3):795–803.
5. Ruiz-Moyano, S., Totten, S. M., Garrido, D. A., Smilowitz, J. T., Bruce German, J., Lebrilla, C. B., and Mills, D. A. (2013). Variation in consumption of human milk oligosaccharides by infant gut- associated strains of bifidobacterium breve. Applied and Environmental Mi- crobiology, 79(19):6040–6049.
6. Duranti, S., Lugli, G. A., Milani, C., James, K., Man- cabelli, L., Turroni, F., Alessandri, G., Mangifesta, M., Mancino, W., Os- siprandi, M. C., Iori, A., Rota, C., Gargano, G., Bernasconi, S., Di Pierro, F., van Sinderen, D., and Ventura, M. (2019). Bifidobacterium bifidum and the infant gut microbiota: an intriguing case of microbe-host co-evolution. Environmental Microbiology, 21(10):3683–3695.
Customized blends of desired functional ingredients in one single, efficient, homogenous premix.